Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 2001

View Archived Issues

Licensing opportunity from NIH: BRCA1 mutants for modulating cellular response to DNA damage

Licensing opportunity from NIH: specific binding agents for KSHV vIL-6

Promising data reported for Visudyne in occult AMD and pathological myopia

IL-1ra protects cortical neurons following transient middle cerebral artery occlusion

Inhale Therapeutic Systems makes significant progress during 2000

American Biogenetic Sciences highlights 2000 progress, provides outlook for 2001

Independent cardiovascular study with Dusa's Levulan begins

Adjunctive treatment with Cerebrolysin associated with neuroprotection in acute ischemic stroke

Effects of BMP-7 in rats with transient MCA occlusion discussed at this week's stroke conference

Inflazyme reports company update

Potent PPAR agonists and their use presented by Merck & Co.

AstraZeneca dedicates resources to discovery of safe neuroprotective compounds

Novel imidazolines only stimulate insulin release during hyperglycemia

Thrombin inhibitors with high selectivity designed at ADIR

Mochida describes new series with potent cholesterol-lowering effects

Pierre Fabre reports imidazolines structurally related to idazoxan and potential uses

Patent issued to Welfide covers new IL-4/IL-5 production inhibitors

Discovery of prostate cancer gene detailed by Myriad

Involvement of MAPK, therapeutic role for MAPK inhibitors in cerebral vasospasm

Draxis Health cleared to begin phase II trials with AMI diagnostic in U.S. and Canada

Genta's Genasense enters phase III evaluation for multiple myeloma

Significant neuroprotective effects demonstrated for kappa opioid agonist

Theratechnologies commences phase II trials in sleep disorders

Dyax and Debiopharm move cystic fibrosis treatment into phase II

Beneficial effects of long-term glucosamine sulfate on osteoarthritis progression

Ilex Oncology acquires Symphar; Symphar becomes Ilex Research-Europe

Potential new agent for reducing NIDDM-associated hyperglycemia without side effects

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...